OKUR: Allosteric, pan-mutant PI3Kα inhibitors OKI-345/355 show high selectivity and strong preclinical efficacy
The event highlighted the scientific rationale and preclinical data supporting allosteric, pan-mutant selective PI3Kα inhibitors for cancer and vascular anomalies. OKI-345 and OKI-355 show high selectivity and efficacy, with INDs planned for 2027 and a focus on safety and patient adherence.Based on…